首页> 美国卫生研究院文献>Cancer Science >Progesterone Receptor A and B Isoforms in the Human Breast and Its Disorders
【2h】

Progesterone Receptor A and B Isoforms in the Human Breast and Its Disorders

机译:人体及其疾病中的孕酮受体A和B亚型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Two different isoforms of progesterone receptor (PR), PRA and PRB, are expressed in target tissues at comparable levels. In this study, we first examined PRA and PRB immunoreactivity in human breast cancer and various intraductal proliferative epithelial lesions, and correlated these findings with clinicopathologic parameters. We then examined mRNA expression of PRA and PRB in six cases of invasive ductal carcinoma using RT‐PCR. Immunoreactivity for both PRA and PRB was positive in the great majority of proliferative disease without atypia (PDWA) (85% for PRA and 96% for PRB) and atypical ductal hyperplasia (ADH) (100% for PRA and 100% for PRB), but the ratio of immunopositive cases and immunohistochemical (IHC) scores was significantly smaller in ductal carcinoma in situ (DCIS) (65% for PRA and 75% for PRB) and invasive ductal carcinoma (IDC) (66% for PRA and 55% for PRB) than in PDWA and ADH. There was a significant positive correlation between IHC scores for PRA and estrogen receptor α (ERα) in IDC, DCIS and ADH but not between PRB and ERα. In IDC, both PRA and PRB IHC scores were significantly associated with histological grade, but there was no association between PRA or PRB status and lymph node involvement, tumor size, or prognosis of the patients. The expression of mRNAs for both PRA and PRB was detected in all six cases of IDC examined. These results suggest that both PRA and PRB are strongly associated with ERa in human breast and this relation may be disturbed in breast cancer.
机译:孕酮受体(PR)的两种不同同工型PRA和PRB在靶组织中的表达水平相当。在这项研究中,我们首先检查了人类乳腺癌和各种导管内增生性上皮病变的PRA和PRB免疫反应性,并将这些发现与临床病理参数相关联。然后,我们使用RT-PCR检查了6例浸润性导管癌中PRA和PRB的mRNA表达。在大多数非典型增生性疾病中,PRA和PRB的免疫反应均为阳性(PDWA)(PRA为85%,PRB为96%)和非典型导管增生(ADH)(PRA为100%,PRB为100%),但是,在原位导管癌(DCIS)中,免疫阳性病例和免疫组化(IHC)分数的比例显着较小(PRA为65%,PRB为75%)和浸润性导管癌(IDC)(PRA为66%,PRC为55%) PRB),而不是PDWA和ADH。 IDC,DCIS和ADH中PRA的IHC得分与雌激素受体α(ERα)之间存在显着的正相关,而PRB和ERα之间的IHC得分却没有显着正相关。在IDC中,PRA和PRB IHC评分均与组织学等级显着相关,但PRA或PRB状态与淋巴结受累,肿瘤大小或患者预后之间没有关联。在所有六例IDC病例中均检测到PRA和PRB的mRNA表达。这些结果表明,PRA和PRB都与人乳腺的ERa密切相关,这种关系在乳腺癌中可能会受到干扰。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号